Rallybio Corp (RLYB) Price

Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. The company is headquartered in New Haven, Connecticut and currently employs 25 full-time employees. The company went IPO on 2021-07-29. The company has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The company has two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Its other product candidates include RLYB114, a C5-targeted Affibody molecule conjugated to polyethylene glycol; RLYB332, a preclinical antibody designed to inhibit MTP-2; and the REV102 Program, a small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1).